MedTrace Logo

Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer

NCT06809426 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2025-02-05

No results posted yet for this study

Summary

Evaluating the safety and antitumor efficacy of 177Lu-LNC1011

Conditions

  • PSMA PET-Positive Castration-Resistant Prostate Cancer

Interventions

DRUG

177Lu-LNC1011

75 mCi (2.78 GBq) of 177Lu-LNC1011 Injection intravenously each time, injections every 6 weeks, not to exceed a total of 6 injections.

Sponsors & Collaborators

  • Affiliated Hospital of Jiangnan University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-21
Primary Completion
2024-10-14
Completion
2024-10-24

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06809426 on ClinicalTrials.gov